论文部分内容阅读
目的 评估国产培高利特 (pergolide)联合左旋多巴治疗中、晚期帕金森病 (PD)的有效性和安全性。方法 对 30例中、晚期 PD患者在原有抗 PD药物的基础上加用培高利特 6周 ,治疗前、后进行临床症状的 Webster评分和各项实验室安全性检查。结果 Webster评分示 7例 (2 3% )有中度疗效 ,13例 (43% )有轻度疗效。5例有“开 -关”现象的患者中 3例明显改善。不良反应主要为胃肠道反应 ,未发现严重毒副作用。结论 对于左旋多巴疗效减退的中、晚期 PD患者加用培高利特是有效且安全的。
Objective To evaluate the efficacy and safety of domestic pergolide combined with levodopa in the treatment of advanced and advanced Parkinson’s disease (PD). Methods 30 cases of middle and advanced PD patients were treated with pergolide on the basis of the original anti-PD drugs for 6 weeks. The Webster score of clinical symptoms and laboratory safety tests were performed before and after treatment. Results The Webster score showed moderate efficacy in 7 patients (23%) and mild efficacy in 13 patients (43%). Three of the five patients with the “on-off” phenomenon improved significantly. Adverse reactions mainly gastrointestinal reactions, no serious side effects were found. Conclusion It is effective and safe to add pergolide to mid-and-late stage PD patients with diminished efficacy of levodopa.